Clinical trials: Pneumonia, Pneumococcal
Pneumonia, Pneumococcal
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of…
- Trial name
- NCT05420961
- Testing
- V116, PCV15, PPSV23
- Where
- 51 sites in United States, Canada and 7 more
- Volunteers
- 717 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcal Pneumonia, Nasopharyngeal Diseases
PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae
A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype…
- Conditions
- Streptococcal Pneumonia, Nasopharyngeal Diseases, Vaccination Adverse Event
- Trial name
- NCT02133469
- Testing
- PCV7 (Pneumococcal 7-Valent Conjugate Vaccine), Hib Vaccine
- Where
- 9 sites in China
- Volunteers
- 3,281 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Pneumonia, Influenza, Human
The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study
The investigators are interested in examining the effect of the Live Attenuated Influenza (flu) Vaccine (LAIV) upon nasal carriage of bacteria called Streptococcus pneumoniae (also known as pneumococcus).
- Trial name
- LAIV/EHPC (NCT03502291)
- Testing
- Study one: LAIV + Inoculation, Study two: Inoculation + LAIV
- Where
- United Kingdom
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Pneumonia, Pneumococcal
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
- Trial name
- NCT04357522
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine, 13-Valent Pneumococcal Conjugate Vaccine
- Where
- 3 sites in China
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumonia, Pneumococcal
Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
The purpose of this study is to assess the safety and tolerability of PATH-wSP, administered intramuscularly to healthy Kenyan adults and toddlers who have been primed with a pneumococcal conjugate vaccine (PCV).
- Trial name
- NCT02097472
- Testing
- PATH-wSP, Synflorix, Pentavac
- Where
- Kenya
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- PATH
Pneumonia, Pneumococcal, Diabetes Mellitus
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
Primary care visits are a key aspect of clinical care focused on helping patients to close care gaps related to preventive care such as vaccination, diabetes testing, statin therapy and cancer screening.
- Conditions
- Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
- Trial name
- NCT05799976
- Testing
- Text message nudge
- Where
- United States
- Volunteers
- 29,334 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
Pneumococcal Pneumonia
Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain
The goals of the study are to determine the pneumococcal polysaccharide vaccination rate in patients with diabetes before and after community pharmacist education and intervention.
- Trial name
- NCT03851978
- Testing
- Pharmacist Vaccine Education
- Where
- 4 sites in United States
- Volunteers
- 431 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
- Trial name
- NCT00334334
- Testing
- Pneumococcal (vaccine)
- Where
- 66 sites in Germany, Poland and 1 more
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections, Pneumonia, Pneumococcal
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114.
- Trial name
- PNEU-TRUE (NCT03950856)
- Testing
- V114, Prevnar 13™
- Where
- 55 sites in United States, Australia and 4 more
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumonia, Pneumococcal, Pneumonia Childhood
Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation
The purpose of this research is to provide baseline surveillance of pneumonia in young children in Malaysia before and during the implementation of the pneumococcal conjugate vaccine (PCV).
- Trial name
- MSIP PCV (NCT04923035)
- Where
- 3 sites in Malaysia
- Volunteers
- 1,010 people, healthy volunteers welcome
- Sponsor
- IMU University, Malaysia
Pneumonia, Pneumococcal
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis.
- Trial name
- NCT04168190
- Testing
- V116, Pneumovax™23
- Where
- 20 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Pneumococcal
Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
The primary objectives of this study are to evaluate the immunogenicity (antibody response) and safety and tolerability of a 2-dose primary series and booster dose (2+1 schedule) of Pneumosil co-administered with routine…
- Trial name
- NCT03896477
- Testing
- Pneumosil, Prevenar 13, Synflorix
- Where
- The Gambia
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- PATH
Pneumonia, Bacterial
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose
The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series…
- Trial name
- NCT07406334
- Testing
- Pn-MAPS30plus, PCV20
- Where
- 2 sites in South Africa
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia
Effectiveness of the PCV13 in Older Thai Adults
This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024.
- Trial name
- NCT06279624
- Where
- Thailand
- Volunteers
- 825 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Meningitis
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper…
- Conditions
- Pneumonia, Meningitis, Bacteraemia, Sepsis
- Trial name
- PCV1103 (NCT01619462)
- Testing
- Prevenar 13 and Synflorix
- Where
- Papua New Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Pneumonia, Pneumococcal
Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months
The purpose of this study is to evaluate safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged above 3 Months.
- Trial name
- NCT04108845
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Streptococcus Pneumoniae Pneumonia
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07025876
- Testing
- low dose PCV24, high dose PCV24, PPV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COPD, Pneumonia
Burden of Hospitalized Pneumonia in Korea COPD Population
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. By 2030, COPD is expected to be the fourth main cause of death.
- Conditions
- COPD, Pneumonia, Pneumococcal Vaccine
- Trial name
- COPDCAP (NCT03046134)
- Testing
- PCV13
- Where
- 4 sites in South Korea
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Chung-Ang University Hospital